Feed AMPE
AM

Ampio Pharmaceuticals, Inc. AMPE · OTC

$0.18 +0.00% (+$0.00)

Summary

42 / 100 · Bulios Score

What speaks for it

  • It holds more cash than debt: $4.09M against $274.0K.

What to watch

  • It passes only 3 of the 9 points of the Piotroski financial health test.
  • The price moves much more than the market (beta 6.09).

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

There is not enough revenue history yet to say how fast it grows.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Yes

It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

50% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2015

By product

By region

The company reports no revenue by region.

Aytu Segment brings in 100% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.